Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Waters Corporation
WAT
NYSE·Healthcare·Medical - Diagnostics & Research·Mkt cap $24.6B
$376.08
▼ -0.54%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$275.05 - $414.15
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 7.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Advanced proprietary technologies
- Comprehensive analytical workflow solutions
- Broad global customer base
- Strong research and development capabilities
Bear Case
1 risk
- Average volatility.
Growth
Mild headwinds expected
Increasing pharmaceutical research spending
Value
Attractively priced below Life Sciences Tools peer average
Momentum
Hot
+24.3% over 3m
Quality
Strong
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying WAT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 4, 2026
MAY 5, 2026
Reported EPS of $2.70 vs $2.31 consensus (+16.9% surprise). Revenue of $1.3B vs $1.2B expected (+5.3%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+16.9%
Next: May 4, 2026
Revenue trend · last 8Q
—
—
+6%
+4%
+9%
+8%
+7%
+91%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$708.5M
$740.3M
$872.7M
$661.7M
$771.3M
$799.9M
$932.4M
$1.3B
Margins · last 8Q
Gross
—
Operating
—
Profit
-5.7%
Wall Street consensus
11 analysts · 27% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
27%
Hold
73%
Sell
0%
Median Price Target
$387.00
▲ +2.9% vs $376.08
Latest: Piper Sandler · Jun 11, 2026
5 analysts covering